Ethambutol interactions
Full monograph for EthambutolCheck it against another medicine
Medicines
239 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Leflunomide | Major | Synergy | The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may… | 3 sources — open the full entry |
| Adalimumab | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Aluminium Hydroxide + Magnesium Hydroxide | Moderate | Absorption | INTERVAL: Concurrent administration of antacids containing aluminum hydroxide may decrease the oral absorption of ethambutol. The exact mechanism of… | 5 sources — open the full entry |
| Aluminium Hydroxide + Magnesium Hydroxide + Simethicone | Moderate | Absorption | INTERVAL: Concurrent administration of antacids containing aluminum hydroxide may decrease the oral absorption of ethambutol. The exact mechanism of… | 5 sources — open the full entry |
| Amiodarone Hydrochloride | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Amlodipine Besilate + Atorvastatin | Moderate | Synergy · Unknown | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk…2 documented mechanisms | 4 sources — open the full entry |
| Atorvastatin + Ezetimibe | Moderate | Synergy · Unknown | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk…2 documented mechanisms | 4 sources — open the full entry |
| Atorvastatin Calcium | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Beclomethasone Dipropionate + Chloramphenicol + Clotrimazole + Lidocaine | Moderate | Synergy · Unknown | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk…2 documented mechanisms | 4 sources — open the full entry |
| Bortezomib | Moderate | Synergy | Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or… | 4 sources — open the full entry |
| Cabazitaxel | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Carbidopa + LevodopaExtended releaseProlonged release | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Carboplatin | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Carfilzomib | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Chloramphenicol (Oral) | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Chloramphenicol + Lidocaine Hydrochloride | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Chloroquine Phosphate | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Cisplatin | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Colchicine | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Crizotinib | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Dapsone | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Dexamethasone + Chloramphenicol | Moderate | Synergy · Unknown | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk…2 documented mechanisms | 4 sources — open the full entry |
| Docetaxel Trihydrate | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Efavirenz | Moderate | Synergy | Coadministration of efavirenz with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Efavirenz has been associated with… | 7 sources — open the full entry |
| Epirubicin Hydrochloride | Moderate | Synergy | The concomitant or sequential use of epirubicin with agents known to induce hepatotoxicity may potentiate the risk of liver injury. Epirubicin undergoes… | 4 sources — open the full entry |
| Eribulin Mesylate | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Etanercept | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Etoposide | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Fludarabine Phosphate | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Fluvastatin | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Golimumab | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Hydroxychloroquine Sulphate | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Infliximab | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Interferon Alfa-2a [Recombinant] | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Isosorbide Dinitrate + Hydralazine Hydrochloride | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| L-Asparginase | Moderate | Synergy | Concomitant use of asparaginase with other hepatotoxic agents may potentiate the risk of liver injury. Hepatomegaly, acute severe hepatotoxicity, and fatal… | 13 sources — open the full entry |
| Levodopa + Benserazide | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Levodopa + Carbidopa | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Levodopa + Carbidopa + Entacapone | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Linezolid | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Methotrexate | Moderate | Synergy | Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Methotrexate, especially at higher… | 3 sources — open the full entry |
| Metronidazole | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Metronidazole + Miconazole Nitrate | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Metronidazole + Neomycin Sulphate + Polymyxin B + Nystatin | Moderate | Synergy · Unknown | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk…2 documented mechanisms | 4 sources — open the full entry |
| Nab-Paclitaxel [Nanoparticle Albumin-Bound Paclitaxel] | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Nitrofurantoin | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Nitrofurantoin + Nitrofurantoin Microcrystals | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Oxaliplatin | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Paclitaxel | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Peginterferon alfa-2a [Pegylated Interferon alfa-2a] | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
Conditions
Conditions in which Ethambutol needs care, as documented in this source.
Optic Neuritis
MajorEthambutol is contraindicated in patients with known optic neuritis unless clinical judgement determines that it may be used. Ethambutol can produce decreases in visual acuity which appear to be due to optic neuritis. This may be related to dose and duration of treatment, and is generally reversible when administration of the drug is discontinued promptly. However, irreversible blindness has been reported. Ethambutol should not be used in patients who are unable to identify and report visual side effects or changes in vision such as young children or unconscious patients. It should be administered cautiously and only after careful consideration of risks and benefits in patients with preexisting visual defects such as cataracts, diabetic retinopathy, or recurrent inflammatory conditions of the eye. Ophthalmologic testing of visual acuity, visual field, and color discrimination is required before and during treatment. However, visual changes may be difficult to evaluate in some cases, since they may be related to the underlying disease rather than the drug.
11 sources
- Lees AW, Allan GW, Smith J, et al. "Toxicity from rifampicin plus isoniazid and rifampicin plus ethambutol therapy." Tubercle 52 (1971): 182-90
- Polak BC, Leys M, van Lith GH "Blue-yellow colour vision changes as early symptoms of ethambutol oculotoxicity." Ophthalmology 191 (1985): 223-6
- Chatterjee VK, Buchanan DR, Friedmann AI, Green M "Ocular toxicity following ethambutol in standard dosage." Br J Dis Chest 80 (1986): 288-91
- Joubert PH, Strobele JG, Ogle CW, van der Merwe CA "Subclinical impairment of colour vision in patients receiving ethambutol." Br J Clin Pharmacol 21 (1986): 213-6
- DeVita EG, Miao M, Sadun AA "Optic neuropathy in ethambutol-treated renal tuberculosis." J Clin Neuroophthalmol 7 (1987): 77-83
- Jimenez-Lucho VE, del Busto R, Odel J "Isoniazid and ethambutol as a cause of optic neuropathy." Eur J Respir Dis 71 (1987): 42-5
- Kahana LM "Toxic ocular effects of ethambutol." Can Med Assoc J 137 (1987): 213-6
- Bandopadhya P, Dash RJ "Toxic ocular effects of ethambutol." Can Med Assoc J 138 (1988): 493
Show all 11 sourcesShow fewer sources
- Schild HS, Fox BC "Rapid-onset reversible ocular toxicity from ethambutol therapy." Am J Med 90 (1991): 404-6
- Smith JL "Should ethambutol be barred?" J Clin Neuroophthalmol 7 (1987): 84-6
- "Product Information. Myambutol (ethambutol)." Lederle Laboratories (2002):
Hepatic Insufficiency
ModerateLiver toxicities including fatalities have been reported when using ethambutol. Caution is advised, especially if using in patients with hepatic impairment. Baseline and periodic assessment of hepatic function should be performed.
1 source
- "Product Information. Myambutol (ethambutol)." Lederle Laboratories (2002):
Hyperuricemia
ModerateEthambutol may commonly cause hyperuricemia, which has been reported in up to two-thirds of treated patients. Occasionally, it has led to joint arthralgias and gouty arthritis after 1 to 2 months of therapy. Serum uric acid levels should be monitored in patients with preexisting hyperuricemia or gout during ethambutol therapy, and appropriate measures (e.g., administration of uricosuric agents) taken to prevent the development or exacerbation of gout.
5 sources
- Postlethwaite AE, Bartel AG, Kelley WN "Hyperuricemia due to ethambutol." N Engl J Med 286 (1972): 761-2
- Khanna BK "Acute gouty arthritis following ethambutol therapy." Br J Dis Chest 74 (1980): 409-10
- Narang RK, Agarwal MC, Raina AK, et al. "Hyperuricaemia induced by ethambutol." Br J Dis Chest 77 (1983): 403-6
- Khanna BK, Gupta VP, Singh MP "Ethambutol-induced hyperuricaemia." Tubercle 65 (1984): 195-9
- "Product Information. Myambutol (ethambutol)." Lederle Laboratories (2002):
Kidney Diseases
ModerateEthambutol is primarily eliminated by the kidney. Patients with renal impairment may be at greater risk for adverse effects from ethambutol, including optic neuritis, due to decreased drug clearance. Therapy with ethambutol should be administered cautiously in patients with renal impairment. Dosage adjustments are recommended in moderate renal impairment but should be based on serum levels of ethambutol.
7 sources
- Collier J, Joekes AM, Philalithis PE, Thompson FD "Two cases of ethambutol nephrotoxicity." Br Med J 11/06/76 (1976): 1105-6
- Stone WJ, Waldron JA, Dixon JH, et al. "Acute diffuse interstitial nephritis related to chemotherapy of tuberculosis." Antimicrob Agents Chemother 10 (1976): 164-72
- Garcia-Martin F, Mampaso F, de Arriba G, et al. "Acute interstitial nephritis induced by ethambutol." Nephron 59 (1991): 679-80
- Varughese A, Brater DC, Benet LZ, Lee C-S "Ethambutol kinetics in patients with impaired renal function." Am Rev Respir Dis 134 (1986): 34-8
- Insel J, Mirvis DM, Boland MJ, Cinquegrani MP, Shanes J, Rubin SA, Whalen JJ "A multicenter study of the safety and efficacy of benazepril hydrochloride, a long-acting angiotensin-converting enzyme inhibitor, in patients with chronic congestive heart failure." Clin Pharmacol Ther 45 (1989): 312-20
- De Feo P, Torlone E, Perriello G, Fanelli C, Epifano L, Di Vincenzo A, Modarelli F, Motolese M, Brunetti P, Bolli GB "Short-term metabolic effects of the ACE-inhibitor benazepril in type 2 diabetes mellitus associated with arterial hypertension." Diabete Metab 18 (1992): 283-8
- "Product Information. Myambutol (ethambutol)." Lederle Laboratories (2002):
Therapeutic duplication
Drug classes that overlap with Ethambutol, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
miscellaneous antituberculosis a
The recommended maximum number of medicines in the 'miscellaneous antituberculosis agents' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'miscellaneous antituberculosis agents' category.
Example product in the source data (US market): Rifater